Post by @sasha.withlove

Studies on GLP-1 medications & thyroid cancer ⬇️ 1. Pasternak B. et al. (2024), BMJ “Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.” 145,410 GLP-1 users — no increased risk of thyroid cancer found. DOI: 10.1136/bmj-2023-078225 (BMJ) 2. Hu W. et al. (2022), Frontiers in Endocrinology “Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: A Meta-Analysis of Randomized Controlled Trials.” Meta-analysis of 45 randomized trials / 94,063 participants — no significant increase in thyroid cancer or thyroid masses. (Frontiers) 3. “Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules” (2025) Study of 171,460 GLP-1 users with thyroid nodules — no significant increase in thyroid cancer risk compared with metformin (RR 0.99; 95% CI 0.96–1.03). (PubMed) Bottom line: Current human evidence does not demonstrate an increased risk of thyroid cancer with GLP-1 receptor agonists, including available evidence in patients with pre-existing thyroid nodules. (BMJ) ⚠️ For informational purposes only. Individual results and risks may vary. Consult a medical professional. #GlowUp #beautytips #beforeandafter